To include your compound in the COVID-19 Resource Center, submit it here.

Abgenix and Dyax in antibody technology deal

By BC Staff | Jan 8, 2001 | 8:00 AM GMT

The companies will combine ABGX's XenoMouse technology

Read the full 73 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE